|
1. BIOLOGIE
|
|
|
|
2.6 ETIOLOGIE - ENVIRONNEMENT
|
|
|
|
3.1.1 PRÉVENTION - TABAC - E-CIGS
|
|
|
|
3.8 PRÉVENTION - ALIMENTATION
|
|
|
|
4. DÉPISTAGE, DIAGNOSTIC ET PRONOSTIC
|
|
|
|
4.10 DÉP., DIAG. & PRONO. - POUMON
|
|
|
Screening for lung cancer based on risk could save lives [University of Michigan]
|
|
|
|
|
|
Current lung cancer screening is based on age (ages 55 to 80), on how much individuals have smoked (measured as pack-years), and how long they have stopped smoking. The team looked at various risk-prediction models that consider behavior, lifestyle and family history to estimate the probability of getting or dying from lung cancer. CISNET published its findings this week in the Journal of the National Cancer Institute.
|
|
|
|
|
|
|
5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE
|
|
|
A promising antibody [Kiel University]
|
|
|
|
|
|
The research team carried out fundamental combination experiments on mice using the antibody daratumumab to test for possible effectiveness against T-ALL cancer cells. In doing so, they also compared antibody treatment alone with a combination of antibody and chemotherapy.
|
|
|
|
|
|
|
5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES
|
|
|
|
5.12.5 IMMUNOTHÉRAPIES - PHARMA
|
|
|
|
5.17 TRAITEMENTS - RADIOTHÉRAPIE
|
|
|
|
5.2 PHARMA
|
|
|
|
5.3 TRAITEMENTS - FDA, EMA, NICE...
|
|
|
|
Patient-focused drug development: New FDA draft guidance delves into what’s important [EndPoints]
|
|
|
|
|
|
In determining what’s important, the FDA recommends that sponsors use qualitative research methods, which can generate in-depth thoughts from patients in their own words through interviews or focus groups, quantitative research methods, which can use statistical methods to summarize the collective patient experience data, or mixed-methods research, which can combine qualitative and quantitative methods to understand the patient experience.
|
|
|
|
|
|
|
|
5.6 ESMO
|
|
|
|
|
5.6.13 ESMO - PROSTATE
|
|
|
|
|
6.6 PUBLICATIONS
|
|
|
|
6.7.1 IA/BIOINFORMATIQUE
|
|
|